506 related articles for article (PubMed ID: 36316602)
1. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H; Zhou X; Fu D; Le C; Wang J; Zhou Q; Liu X; Yuan Y; Ding K; Xiao Q
Cancer Commun (Lond); 2023 Jan; 43(1):42-74. PubMed ID: 36316602
[TBL] [Abstract][Full Text] [Related]
2. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Waters AM; Der CJ
Cold Spring Harb Perspect Med; 2018 Sep; 8(9):. PubMed ID: 29229669
[No Abstract] [Full Text] [Related]
3. The current state of the art and future trends in RAS-targeted cancer therapies.
Punekar SR; Velcheti V; Neel BG; Wong KK
Nat Rev Clin Oncol; 2022 Oct; 19(10):637-655. PubMed ID: 36028717
[TBL] [Abstract][Full Text] [Related]
4. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
5. A model for RAS mutation patterns in cancers: finding the sweet spot.
Li S; Balmain A; Counter CM
Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
[TBL] [Abstract][Full Text] [Related]
6. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
7. KRAS G12C inhibition and innate immune targeting.
Tani T; Kitajima S; Conway EB; Knelson EH; Barbie DA
Expert Opin Ther Targets; 2021 Mar; 25(3):167-174. PubMed ID: 33703985
[TBL] [Abstract][Full Text] [Related]
8. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
9. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
11. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
12. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J; Molina-Arcas M; Downward J
Clin Cancer Res; 2023 Dec; 29(24):5012-5020. PubMed ID: 37581538
[TBL] [Abstract][Full Text] [Related]
13. Mutated RAS: Targeting the "Untargetable" with T Cells.
Chatani PD; Yang JC
Clin Cancer Res; 2020 Feb; 26(3):537-544. PubMed ID: 31511296
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.
Hamilton G; Plangger A
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1065-1074. PubMed ID: 34347509
[TBL] [Abstract][Full Text] [Related]
15. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract][Full Text] [Related]
16. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
17. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
18. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).
Zhang Z; Guiley KZ; Shokat KM
Nat Chem Biol; 2022 Nov; 18(11):1177-1183. PubMed ID: 35864332
[TBL] [Abstract][Full Text] [Related]
19. Selective and noncovalent targeting of RAS mutants for inhibition and degradation.
Teng KW; Tsai ST; Hattori T; Fedele C; Koide A; Yang C; Hou X; Zhang Y; Neel BG; O'Bryan JP; Koide S
Nat Commun; 2021 May; 12(1):2656. PubMed ID: 33976200
[TBL] [Abstract][Full Text] [Related]
20. Searching for treatments for non-G12C-KRAS mutant cancers.
Guo C; Banerji U
Br J Cancer; 2021 Aug; 125(5):625-626. PubMed ID: 33859342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
